سعر مانيتول 20% فيبكو محلول وريدي 500 مل 2022

Mannitol 20% solution for intravenous infusion, 500 ml; an osmotic diuretic used in hospitals.

• Reduction of intracranial pressure and treatment of cerebral edemaPopulation: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)
• Reduction of elevated intraocular pressurePopulation: Adults and pediatric patientsDailyMed (U.S. National Library of Medicine)

• Reported adverse reactions include hypersensitivity reactions (anaphylaxis, hypotension, dyspnea, fever, chills, urticaria, rash, nausea, vomiting, headache), renal failure (acute kidney injury, osmotic nephrosis, oliguria, anuria, hematuria, polyuria), CNS toxicity (coma, seizures, confusion, lethargy, dizziness, rebound intracranial pressure), fluid and electrolyte disorders, infusion-site reactions, congestive heart failure, pulmonary edema, palpitations, thirst, dry mouth, asthenia and malaise.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to mannitol.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Anuria.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Severe hypovolemia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious hypersensitivity reactions, including anaphylaxis, hypotension and dyspnea resulting in cardiac arrest and death, have been reported; stop the infusion immediately if hypersensitivity is suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Renal complications, including irreversible renal failure and reversible oliguric acute kidney injury (osmotic nephrosis), have occurred, even in patients with normal renal function who received large doses.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• CNS toxicity (confusion, lethargy, coma), some fatal, especially with impaired renal function; a rebound rise in intracranial pressure may occur several hours after infusion, and with a compromised blood-brain barrier repeated use may increase cerebral edema.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Nephrotoxic drugs (e.g., cyclosporine, aminoglycosides)Increase the risk of renal failure after mannitol; avoid concomitant use if possible.DailyMed (U.S. National Library of Medicine)
• Other diureticsMay potentiate the renal toxicity of mannitol; avoid concomitant use if possible.DailyMed (U.S. National Library of Medicine)
• Systemic neurotoxic drugs (e.g., aminoglycosides)May potentiate the CNS toxicity of mannitol; avoid concomitant use if possible.DailyMed (U.S. National Library of Medicine)

• Case-report data over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Mannitol crosses the placenta and may cause fluid shifts that could potentially harm the fetus; no adverse developmental effects were reported in published animal studies.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on mannitol in human or animal milk, effects on the breastfed infant or milk production; weigh the benefits of breastfeeding against the mother's clinical need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Mannitol: Given intravenously, mannitol stays largely in the extracellular space, raises the osmolarity of plasma and glomerular filtrate, limits tubular water reabsorption and increases sodium and chloride excretion; the osmotic gradient draws water out of cells, which lowers intracranial and intraocular pressure.